{"id":634883,"date":"2023-01-20T15:44:02","date_gmt":"2023-01-20T15:44:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=634883"},"modified":"2023-01-20T15:44:02","modified_gmt":"2023-01-20T15:44:02","slug":"glioblastoma-multiforme-market-to-exhibit-moderate-growth-rate-till-20222032-investigates-delveinsight-key-companies-northwest-therapeutics-bayer-astrazeneca-dnatrix-chimerix","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/glioblastoma-multiforme-market-to-exhibit-moderate-growth-rate-till-20222032-investigates-delveinsight-key-companies-northwest-therapeutics-bayer-astrazeneca-dnatrix-chimerix_634883.html","title":{"rendered":"Glioblastoma Multiforme Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies &#8211; Northwest Therapeutics, Bayer, AstraZeneca, DNAtrix, Chimerix"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1674237142.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Glioblastoma Multiforme Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies - Northwest Therapeutics, Bayer, AstraZeneca, DNAtrix, Chimerix\" src=\"https:\/\/www.abnewswire.com\/uploads\/1674237142.jpeg\" alt=\"Glioblastoma Multiforme Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies - Northwest Therapeutics, Bayer, AstraZeneca, DNAtrix, Chimerix\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Glioblastoma Multiforme market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Glioblastoma Multiforme pipeline products will significantly revolutionize the Glioblastoma Multiforme market dynamics.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&ldquo;Glioblastoma Multiforme Market Insights, Epidemiology, and Market Forecast-2032&Prime;<\/strong> report offers an in-depth understanding of the Glioblastoma Multiforme, historical and forecasted epidemiology as well as the Glioblastoma Multiforme market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Glioblastoma Multiforme market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current &amp; forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers &amp; barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the Glioblastoma Multiforme market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/glioblastoma-multiforme-gbm-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Glioblastoma Multiforme Market Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Glioblastoma Multiforme Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Glioblastoma Multiforme (GBM) is the most frequently occurring type of primary tumors of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved despite the fact that the innovative diagnostic strategies and new therapies have been developed. Glioblastoma Multiforme is a grade IV glioma according to the WHO 2007 classification and is the most common and lethal primary malignancy of the central nervous system.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Glioblastoma Multiforme Market Report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Glioblastoma Multiforme market size is anticipated to grow with a significant <strong>CAGR<\/strong> during the study period (2019-2032)<\/li>\n<li>The National Cancer Institute estimates that <strong>22,850 adults<\/strong> (12,630 men and 10,280 women) were diagnosed with brain and other nervous system cancer in 2015. It also estimates that&nbsp;<strong>15,320<\/strong> of these diagnoses resulted in death<\/li>\n<li><strong>In June 2022,<\/strong> Novartis announced that the US FDA has granted accelerated approval to TAFINLAR (dabrafenib) + MEKINIST (trametinib) for the treatment of advanced tumors that have a mutation called &ldquo;BRAF V600E.&rdquo;<\/li>\n<li>According to the <strong>American Association of Neurological Surgeons<\/strong>, GBM has an incidence of <strong>2&ndash;3 per 100,000 adults<\/strong> per year, and accounts for <strong>52%<\/strong> of all primary brain tumors. Overall, GBM accounts for about <strong>17%<\/strong> of all tumors of the brain (primary and metastatic)<\/li>\n<li>The total incident population of Glioblastoma Multiforme in the 7MM was <strong>32,546<\/strong> in 2021. In case of GBM patients in the United States, the incident cases were 13,251 in 2021<\/li>\n<li><strong>Key Glioblastoma Multiforme Companies:<\/strong> Northwest Therapeutics, Bayer, AstraZeneca, DNAtrix, Chimerix, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Kintara Therapeutics, and others<\/li>\n<li><strong>Key Glioblastoma Multiforme Therapies:<\/strong> DCVax-L, Regorafenib, Durvalumab, DNX-2401, ONC201, Paxalisib(GDC-0084), AV-GBM-1, MDNA55, VAL-083, and others<\/li>\n<li>The Glioblastoma Multiforme epidemiology based on gender analyzed that Glioblastoma Multiforme is more prevalent among males than females<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the Glioblastoma Multiforme Market Report &#8211;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/glioblastoma-multiforme-gbm-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/sample-request\/glioblastoma-multiforme-gbm-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key benefits of the Glioblastoma Multiforme Market report:<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Glioblastoma Multiforme market report covers a descriptive overview and comprehensive insight of the Glioblastoma Multiforme Epidemiology and Glioblastoma Multiforme market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/li>\n<li>The Glioblastoma Multiforme market report provides insights on the current and emerging therapies.<\/li>\n<li>Glioblastoma Multiforme market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n<li>The Glioblastoma Multiforme market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Glioblastoma Multiforme market.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Glioblastoma Multiforme epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/glioblastoma-multiforme-gbm-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Glioblastoma Multiforme Epidemiological Insights<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Glioblastoma Multiforme Market &nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The dynamics of the Glioblastoma Multiforme market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. &nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Glioblastoma Multiforme Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Glioblastoma Multiforme Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Glioblastoma Multiforme market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalence of Glioblastoma Multiforme<\/li>\n<li>Prevalent Cases of Glioblastoma Multiforme by severity<\/li>\n<li>Gender-specific Prevalence of Glioblastoma Multiforme<\/li>\n<li>Diagnosed Cases of Episodic and Chronic Glioblastoma Multiforme<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Glioblastoma Multiforme Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Glioblastoma Multiforme market or expected to get launched during the study period. The analysis covers Glioblastoma Multiforme market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the Glioblastoma Multiforme Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Glioblastoma Multiforme market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/glioblastoma-multiforme-gbm-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Glioblastoma Multiforme market forecast<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Glioblastoma Multiforme Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>DCVax-L:<\/strong> Northwest Therapeutics<\/li>\n<li><strong>Regorafenib:<\/strong> Bayer<\/li>\n<li><strong>Durvalumab:<\/strong> AstraZeneca<\/li>\n<li><strong>DNX-2401:<\/strong> DNAtrix<\/li>\n<li><strong>ONC201:<\/strong> Chimerix<\/li>\n<li><strong>Paxalisib(GDC-0084):<\/strong> Kazia Therapeutics<\/li>\n<li><strong>AV-GBM-1:<\/strong> Aivita Biomedical<\/li>\n<li><strong>MDNA55:<\/strong> Medicenna Therapeutics<\/li>\n<li><strong>VAL-083:<\/strong> Kintara Therapeutics<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Glioblastoma Multiforme Market Strengths<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Vaccine approaches are an attractive adjuvant therapy for solid tumors because they can generate long-term immune surveillance against cancer cells. MimiVax (SurVaxM), Immunomic Therapeutics (ITI-1000), and IMVAX (IGV-001) are some of the key players developing therapeutic vaccines for Glioblastoma Multiforme<\/li>\n<li>Owing to the launch of bevacizumab biosimilars, a reduction in cost burden can be witnessed<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Glioblastoma Multiforme Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period: 2019&ndash;2032<\/strong><\/li>\n<li><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key Glioblastoma Multiforme Companies:<\/strong> Northwest Therapeutics, Bayer, AstraZeneca, DNAtrix, Chimerix, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Kintara Therapeutics, and others<\/li>\n<li><strong>Key Glioblastoma Multiforme Therapies:<\/strong> DCVax-L, Regorafenib, Durvalumab, DNX-2401, ONC201, Paxalisib(GDC-0084), AV-GBM-1, MDNA55, VAL-083, and others<\/li>\n<li><strong>Glioblastoma Multiforme Therapeutic Assessment:<\/strong> Glioblastoma Multiforme current marketed and Glioblastoma Multiforme emerging therapies<\/li>\n<li><strong>Glioblastoma Multiforme Market Dynamics:<\/strong>&nbsp;Glioblastoma Multiforme market drivers and Glioblastoma Multiforme market barriers&nbsp;<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li><strong>Glioblastoma Multiforme Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Glioblastoma Multiforme Market Access and Reimbursement&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Glioblastoma Multiforme Market Opportunities<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Numerous failed clinical trials suggest combination therapies will likely be the most promising method of Glioblastoma Multiforme treatment, and emphasis should be applied to drug design and pharmacokinetic properties<\/li>\n<li>Better prognostic markers would allow physicians to diagnose and begin treatment of GBM at early onset, possibly preventing disease progression<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Glioblastoma Multiforme Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Glioblastoma Multiforme<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Glioblastoma Multiforme<\/p>\n<p style=\"text-align: justify;\">4. Glioblastoma Multiforme Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Glioblastoma Multiforme Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Glioblastoma Multiforme Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Glioblastoma Multiforme Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Glioblastoma Multiforme&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Glioblastoma Multiforme Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Glioblastoma Multiforme Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Glioblastoma Multiforme Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Glioblastoma Multiforme Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Glioblastoma Multiforme Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Glioblastoma Multiforme Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Glioblastoma Multiforme Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Glioblastoma Multiforme Market Barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; Glioblastoma Multiforme Appendix<\/p>\n<p style=\"text-align: justify;\">18. Glioblastoma Multiforme Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Glioblastoma Multiforme treatment, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/glioblastoma-multiforme-gbm-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Glioblastoma Multiforme Medications<\/a> &nbsp;<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=glioblastoma-multiforme-market-to-exhibit-moderate-growth-rate-till-20222032-investigates-delveinsight-key-companies-northwest-therapeutics-bayer-astrazeneca-dnatrix-chimerix\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=glioblastoma-multiforme-market-to-exhibit-moderate-growth-rate-till-20222032-investigates-delveinsight-key-companies-northwest-therapeutics-bayer-astrazeneca-dnatrix-chimerix\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Glioblastoma Multiforme market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Glioblastoma Multiforme pipeline products will significantly revolutionize the Glioblastoma Multiforme market dynamics. DelveInsight&rsquo;s &ldquo;Glioblastoma Multiforme Market &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/glioblastoma-multiforme-market-to-exhibit-moderate-growth-rate-till-20222032-investigates-delveinsight-key-companies-northwest-therapeutics-bayer-astrazeneca-dnatrix-chimerix_634883.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-634883","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/634883","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=634883"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/634883\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=634883"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=634883"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=634883"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}